Oncology & Hematology Clinical Trial Experience

A deep bench of knowledge that pairs oncology development expertise with wide-ranging rare disease experience in the largest areas of unmet need, including new treatments in cell and gene therapies and immuno-oncology.

prcom_Asset 1ARROW

The tireless pursuit of novel oncology treatments

The new course of cancer therapy

Precision medicine – devising patient-specific treatments to combat diseases once considered incurable – is radically changing the way the world looks at cancer therapy. The leaders in this field are small biotech and specialty pharmaceutical companies – organizations sometimes no larger than a few people and a single molecule. Our clinical trial expertise helps you get from brilliant idea to life-changing reality.

Why choose Premier?
  • More than 310 hematology and oncology projects completed in the past five years, including multiple rare cancer and cell and gene therapy studies
  • Expertise ranging from small dose-finding studies to large multinational trials
  • Every aspect, from trial design and investigators to sites and patient selection, customized for your indication – including preferential regulatory pathways and other strategies for successful early planning and engagement

ASCO 2022

Visit Premier Research at ASCO

If you’re attending ASCO’s annual meeting in Chicago June 3-7, let’s get together. Stop by Booth 8025 to discover how partnering with Premier Research’s product development experts can help turn brilliant ideas to life-changing therapies. We’d love to discuss how our focus on biotech innovation and our latest pursuits in cell and gene therapy, immuno-oncology, and patient recruitment can set your trial apart.

WHITE PAPER

Adaptive trial designs

With the emergence of precision medicine, we are seeing a shift in how early-phase oncology trials are conducted, including a growing number of Phase 1 trials reporting preliminary response rates. This shift is due in part to an increase in adaptive trial designs.

Featured Resources

White Paper

White Paper

Unlocking the Full Potential of Precision Medicine in Oncology

Webinar

Webinar

Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies

Premier Insight

Premier Insight

#265: Complete Response: Lymphoma Trial A Surprising Success For Five Patients

Oncology Experts

Ayesha A. Pandit, M.D.

Ayesha A. Pandit, M.D.

Vice President, Medical Affairs
Rupa Doshi, Ph.D.

Rupa Doshi, Ph.D.

Vice President, Oncology Strategy
Ashley Herrick, Ph.D.

Ashley Herrick, Ph.D.

Executive Director, Oncology Program Strategy

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.